Changyun Hu

Company: Adept Therapeutics

Job title: Co-Founder & Chief Scientific Officer

Seminars:

Panel Discussion – Preclinical and Clinical Adenosine Receptor Targeting 2:30 pm

Discuss therapeutic and strategic strengths of single receptor targeting vs dual inhibition Examine which aspects of A2AR and A2BR make it a better or worse target than CD73/39Read more

day: Day Two

Targeting Adenosine Pathway With Antagonizing Anti-A2A\zr Antibody to Enhance Anti-Tumor Immunity 2:00 pm

Discuss current molecules targeting adenosine receptors in preclinic and clinics Show the discovery of an antagonizing anti-A2aR antibody to enhance anti-tumor immunityRead more

day: Day Two